Related Experiment Videos
Hypoglycemia associated autonomic failure
Laura Diedrich1, Darleen Sandoval, Stephen N Davis
1715 PRB II, Division of Diabetes & Endocrinology, Vanderbilt University Medical School, Nashville, TN 37232-6303, USA.
Abstract:
Intensively treated patients with diabetes have a three-fold increased risk of severe hypoglycemic episodes with an attendant four percent mortality. These findings, unfortunately undermine attempts to achieve normoglycemia in diabetic patients. It has been proven that antecedent hypoglycemia is a major factor responsible for blunting metabolic, neuroendocrine and also autonomic responses to subsequent hypoglycemia. Diabetic patients with good glycemic control become unable to recognize symptoms of hypoglycemia. Lack of symptoms, or hypoglycemia unawareness, is part of the syndrome called hypoglycemia associated autonomic failure. This syndrome also includes inadequate neuroendocrine hormonal responses and reduced glycemic thresholds for counterregulatory hormonal secretion. Factors regulating the magnitude of hypoglycemia associated autonomic failure include antecedent duration and frequency of hypoglycemia, prior episodes of exercise, and autonomic neuropathy. Understanding the pathophysiology of this syndrome will provide a foundation for therapy aimed at preventing severe hypoglycemia during intensive metabolic control. This article will review our current understanding of the mechanisms responsible for hypoglycemia associated autonomic failure.
Insights
Intensive diabetes treatment increases severe hypoglycemia risk, leading to unawareness and dangerous autonomic failure. Understanding these mechanisms is key to preventing future episodes.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Neuroscience
Background:
- Intensive diabetes management aiming for normoglycemia carries a significant risk of severe hypoglycemia.
- Severe hypoglycemia episodes can lead to hypoglycemia unawareness, a dangerous condition where patients fail to recognize low blood sugar symptoms.
- Hypoglycemia unawareness is part of a broader syndrome: hypoglycemia-associated autonomic failure (HAAF).
Purpose of the Study:
- To review the current understanding of the mechanisms underlying hypoglycemia-associated autonomic failure (HAAF).
- To explore how antecedent hypoglycemia impacts metabolic, neuroendocrine, and autonomic responses to subsequent hypoglycemia.
- To provide a foundation for developing therapies to prevent severe hypoglycemia in intensively treated diabetic patients.
Main Methods:
- Review of existing literature on hypoglycemia pathophysiology in diabetes.
- Analysis of factors influencing the severity and frequency of hypoglycemia-associated autonomic failure.
- Examination of the blunting effect of prior hypoglycemia on counterregulatory responses.
Main Results:
- Intensive diabetes treatment triples the risk of severe hypoglycemia and increases mortality.
- Antecedent hypoglycemia significantly impairs metabolic, neuroendocrine, and autonomic responses to subsequent low blood glucose.
- Hypoglycemia unawareness, characterized by inadequate hormonal responses and reduced glycemic thresholds, is a key component of HAAF.
Conclusions:
- Hypoglycemia-associated autonomic failure (HAAF) is a critical complication of intensive diabetes therapy.
- Understanding the pathophysiology of HAAF, including its contributing factors like duration/frequency of hypoglycemia and autonomic neuropathy, is essential.
- This knowledge is foundational for developing strategies to prevent severe hypoglycemia and improve patient safety during intensive glycemic control.